elegans and mammalian neuronal cultures (Fonte et al, 2011). We propose that a primary mechanism of Abeta toxicity is the formation of membrane-damaging oligomers, which is blocked by the G37L ...

Acumen Pharmaceuticals is developing ACU193 as the first clinical-stage therapeutic to selectively target toxic soluble amyloid-β oligomers (AβOs), which are an early and persistent driver of ...

Weekly subcutaneous administration of sabirnetug was well-tolerated in the Phase 1 study Systemic exposure following subcutaneous administration ...

BUT WE KNOW THERE’S THESE TOXIC AGGREGATES. THEY’RE CALLED OLIGOMERS. THEY CAN START TO FORM MORE THAN A DECADE BEFORE SYMPTOMS APPEAR AND BEFORE OTHER KNOWN DISEASE MARKERS FORM. THE ABILITY ...

Expansion of trinucleotide repeats, such as CAG that encodes for polyglutamine, is associated with a number of neurodegenerative disorders. Expanded polyglutamine fragments form aggregates that have ...

Most pathological aggregates, called oligomers, are difficult to study with traditional methods, due to their fleeting nature and structural variability. Antibodies, known for their precise target ...

Investigators released the cause of death for Gene Hackman and his wife Betsy Arakawa on Friday. The New Mexico Office of the Medical Investigator says Hackman died from a cardiovascular disease with ...

Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers for the treatment of ...

Rapid Enrollment and Dosing of First Patients Encouraging and Underscores Unmet Need for Better Treatment Options for ...

NEW YORK, March 18, 2025 (GLOBE NEWSWIRE) -- Today's Marketplace (TMP) is proud to announce a featured interview with Acumen Pharmaceuticals (NASDAQ: ABOS) CEO Daniel O ' Connell and Jessica Clark, ...